Celgene adds big OK for Otezla; Vitae takes a haircut on IPO price; ZS touts PhIII hyperkalemia data;

@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech

@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce

@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce

> Celgene ($CELG) added a big approval for Otezla, gaining the FDA's approval to market the drug for psoriasis. Story

> Vitae Pharmaceuticals ($VTAE) priced its IPO at $8 a share, well below its proposed range of $11 to $13 a share. Release

> Texas-based ZS Pharma ($ZSPH) says it garnered positive data for its second Phase III clinical trial of ZS-9 (sodium zirconium cyclosilicate), which has been in the clinic for hyperkalemia. Release

Medical Device News

@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2

@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce

> Little is known about the Sunshine Act site ahead of launch, AdvaMed says. Article

> FDA to weigh in on cybersecurity concerns. Report

Pharma News

@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce

> GlaxoSmithKline soon to name RBS chair Hampton as next chairman. Report

> Oh, what a tangled web of pharma M&A, starring Pfizer, Actavis, Allergan and Salix. Story

> Ackman threatens Allergan with lawsuit if Salix deal is sealed. Article

Drug Delivery News

> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item

> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report

> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story

> Titan Pharma trial of implant for addicts on track. Article

> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More

Diagnostics News

> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News

> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report

> Sequenom keeps prenatal Dx competition running with new positive data. Article

> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story

> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More

Pharma Marketing News

> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report

> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More

> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item

> Can copay coupons be kickbacks? HHS says yes. More

> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.